Development of a New Family of Small Molecule Therapeutics for the Treatment of Chronic Inflammation

Investigators: Maja Edenius, PhD, Research Fellow
Funder(s): Harvard University Technology Development Accelerator Fund

Drs. Whitman and Keller are working as co-principal investigators in collaboration with Anjana Rao, of the Immune Disease Institute at Children’s Hospital Boston. They are developing a new family of small molecule therapeutics for the treatment of chronic inflammatory conditions and autoimmune diseases. 

Established by the Office of the Provost and Office of Technology Development, the Accelerator Fund is an innovative program designed to fund early-stage applied and translational research with manifest commercial potential. Providing critical support to advance potentially important but nascent technologies is key, given the absence of early-stage funding from industry sources.